Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Free-IgE as a Predictor of Responsiveness to Omalizumab in Oral Corticosteroid-Dependent Asthma Patients

  • Domingo, Christian|||0000-0001-8358-773X
  • Monserrate Mitchell, Daniel-Ross
  • Ollert, Marcus|||0000-0002-8055-0103
  • Pomares, Xavier|||0000-0002-2783-414X
  • Forne, Carles|||0000-0002-8133-3274
  • del Estal, Jorge|||0000-0001-7299-2211
  • Amengual Guedan, Maria Jose|||0000-0002-5385-3061
To date, no biomarkers have been found that are able to predict the clinical response to omalizumab. The aim of this study was to assess whether blood concentration of free Immunoglobulin E (IgE) can predict response to treatment with this monoclonal antibody. In a group of patients who were candidates for omalizumab treatment, forced spirometry and blood IgE were measured at entry and at each six-month visit, and free-IgE blood concentrations were measured at month 6. At month 18, the OMADORE protocol was applied. The complete follow-up lasted 30 months. Patients were considered responders if they met at least one of the following criteria: increase in forced expiratory volume in one second (FEV) at the follow-up visit compared to baseline; reduction in corticosteroid dose at the last visit compared to baseline; reduction in omalizumab dose at the follow-up visit; a positive score on the composite index combining all three criteria. The biomarker used to predict treatment response was the free IgE value and the percentage of free IgE to total IgE measured at visit 1, after six months of omalizumab treatment. The percentage of responders varied according to the parameter used (FEV, omalizumab, corticosteroid dose, and the composite index; 45.2%, 64.5%, 48.4%, and 77.4%, respectively). IgE blockade was around 97% both for the group as a whole and for the subgroups. There were no differences in free IgE values nor in the ratio of free IgE to total IgE between responders and non-responders. These results confirm that there is a group of patients who may benefit from the reduction/withdrawal of omalizumab. Determination of free IgE six months after initiation of omalizumab treatment does not discriminate between responders and non-responders.
Repisalud
Publication Artículo científico (JournalArticle)

Functional Characterization of a Dual Enhancer/Promoter Regulatory Element Leading Human CD69 Expression

  • Redondo-Anton, Jennifer
  • Gomez Fontela, Miguel
  • Notario, Laura
  • Raul, Torres-Ruiz
  • Rodríguez-Perales, Sandra
  • Lorente, Elena
  • Lauzurica, Pilar
The CD69 gene encodes a C-type lectin glycoprotein with immune regulatory properties which is expressed on the cell surfaces of all activated hematopoietic cells. CD69 activation kinetics differ by developmental stage, cell linage and activating conditions, and these differences have been attributed to the participation of complex gene regulatory networks. An evolutionarily conserved regulatory element, CNS2, located 4kb upstream of the CD69 gene transcriptional start site, has been proposed as the major candidate governing the gene transcriptional activation program. To investigate the function of human CNS2, we studied the effect of its endogenous elimination via CRISPR-Cas9 on CD69 protein and mRNA expression levels in various immune cell lines. Even when the entire promoter region was maintained, CNS2-/- cells did not express CD69, thus indicating that CNS2 has promoter-like characteristics. However, like enhancers, inverted CNS2 sustained transcription, although at a diminished levels, thereby suggesting that it has dual promoter and enhancer functions. Episomal luciferase assays further suggested that both functions are combined within the CNS2 regulatory element. In addition, CNS2 directs its own bidirectional transcription into two different enhancer-derived RNAs molecules (eRNAs) which are transcribed from two independent transcriptional start sites in opposite directions. This eRNA transcription is dependent on only the enhancer sequence itself, because in the absence of the CD69 promoter, sufficient RNA polymerase II levels are maintained at CNS2 to drive eRNA expression. Here, we describe a regulatory element with overlapping promoter and enhancer functions, which is essential for CD69 gene transcriptional regulation.
Repisalud
Publication Artículo científico (JournalArticle)

In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells.

  • Martinez-Lage, M
  • Raul, Torres-Ruiz
  • Puig-Serra, P
  • Moreno-Gaona, P
  • Martin, M C
  • Moya, F J
  • Quintana-Bustamante, O
  • Garcia-Silva, S
  • Carcaboso, A M
  • Petazzi, P
  • Bueno, C
  • Mora, J
  • Peinado, H
  • Segovia, J C
  • Menendez, P
  • Rodriguez Perales, Sandra
Fusion oncogenes (FOs) are common in many cancer types and are powerful drivers of tumor development. Because their expression is exclusive to cancer cells and their elimination induces cell apoptosis in FO-driven cancers, FOs are attractive therapeutic targets. However, specifically targeting the resulting chimeric products is challenging. Based on CRISPR/Cas9 technology, here we devise a simple, efficient and non-patient-specific gene-editing strategy through targeting of two introns of the genes involved in the rearrangement, allowing for robust disruption of the FO specifically in cancer cells. As a proof-of-concept of its potential, we demonstrate the efficacy of intron-based targeting of transcription factors or tyrosine kinase FOs in reducing tumor burden/mortality in in vivo models. The FO targeting approach presented here might open new horizons for the selective elimination of cancer cells.
Repisalud
Publication Artículo científico (JournalArticle)

CRISPR/Cas9 for Cancer Therapy: Hopes and Challenges

  • Martinez-Lage, Marta
  • Puig-Serra, Pilar
  • Menéndez, Pablo
  • Torres-Ruiz Raul, Raul
  • Rodriguez Perales, Sandra
Cancer is the second leading cause of death globally and remains a major economic and social burden. Although our understanding of cancer at the molecular level continues to improve, more effort is needed to develop new therapeutic tools and approaches exploiting these advances. Because of its high efficiency and accuracy, the CRISPR-Cas9 genome editing technique has recently emerged as a potentially powerful tool in the arsenal of cancer therapy. Among its many applications, CRISPR-Cas9 has shown an unprecedented clinical potential to discover novel targets for cancer therapy and to dissect chemical-genetic interactions, providing insight into how tumours respond to drug treatment. Moreover, CRISPR-Cas9 can be employed to rapidly engineer immune cells and oncolytic viruses for cancer immunotherapeutic applications. Perhaps more importantly, the ability of CRISPR-Cas9 to accurately edit genes, not only in cell culture models and model organisms but also in humans, allows its use in therapeutic explorations. In this review, we discuss important considerations for the use of CRISPR/Cas9 in therapeutic settings and major challenges that will need to be addressed prior to its clinical translation for a complex and polygenic disease such as cancer.
Repisalud
Publication Artículo científico (JournalArticle)

Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture.

  • Álvarez, Eva G
  • Demeulemeester, Jonas
  • Otero, Paula
  • Jolly, Clemency
  • García-Souto, Daniel
  • Pequeño-Valtierra, Ana
  • Zamora, Jorge
  • Tojo, Marta
  • Temes, Javier
  • Baez-Ortega, Adrian
  • Rodriguez-Martin, Bernardo
  • Oitaben, Ana
  • Bruzos, Alicia L
  • Martínez-Fernández, Mónica
  • Haase, Kerstin
  • Zumalave, Sonia
  • Abal, Rosanna
  • Rodríguez-Castro, Jorge
  • Rodriguez-Casanova, Aitor
  • Diaz-Lagares, Angel
  • Li, Yilong
  • Raine, Keiran M
  • Butler, Adam P
  • Otero, Iago
  • Ono, Atsushi
  • Aikata, Hiroshi
  • Chayama, Kazuaki
  • Ueno, Masaki
  • Hayami, Shinya
  • Yamaue, Hiroki
  • Maejima, Kazuhiro
  • Blanco, Miguel G
  • Forns, Xavier
  • Rivas, Carmen
  • Ruiz-Bañobre, Juan
  • Pérez-Del-Pulgar, Sofía
  • Torres-Ruiz, Raul
  • Rodriguez Perales, Sandra
  • Garaigorta, Urtzi
  • Tubio, Jose M C
  • Campbell, Peter J
  • Nakagawa, Hidewaki
  • Van Loo, Peter
Most cancers are characterized by the somatic acquisition of genomic rearrangements during tumour evolution that eventually drive the oncogenesis. Here, using multiplatform sequencing technologies, we identify and characterize a remarkable mutational mechanism in human hepatocellular carcinoma caused by Hepatitis B virus, by which DNA molecules from the virus are inserted into the tumour genome causing dramatic changes in its configuration, including non-homologous chromosomal fusions, dicentric chromosomes and megabase-size telomeric deletions. This aberrant mutational mechanism, present in at least 8% of all HCC tumours, can provide the driver rearrangements that a cancer clone requires to survive and grow, including loss of relevant tumour suppressor genes. Most of these events are clonal and occur early during liver cancer evolution. Real-time timing estimation reveals some HBV-mediated rearrangements occur as early as two decades before cancer diagnosis. Overall, these data underscore the importance of characterising liver cancer genomes for patterns of HBV integration.
Repisalud
Publication Reseña (Review)

CRISPR Approaches for the Diagnosis of Human Diseases.

  • Puig-Serra, Pilar
  • Casado-Rosas, Maria Cruz
  • Martinez-Lage, Marta
  • Olalla-Sastre, Beatriz
  • Alonso-Yanez, Alejandro
  • Torres-Ruiz, Raul
  • Rodriguez Perales, Sandra
CRISPR/Cas is a prokaryotic self-defense system, widely known for its use as a gene-editing tool. Because of their high specificity to detect DNA and RNA sequences, different CRISPR systems have been adapted for nucleic acid detection. CRISPR detection technologies differ highly among them, since they are based on four of the six major subtypes of CRISPR systems. In just 5 years, the CRISPR diagnostic field has rapidly expanded, growing from a set of specific molecular biology discoveries to multiple FDA-authorized COVID-19 tests and the establishment of several companies. CRISPR-based detection methods are coupled with pre-existing preamplification and readout technologies, achieving sensitivity and reproducibility comparable to the current gold standard nucleic acid detection methods. Moreover, they are very versatile, can be easily implemented to detect emerging pathogens and new clinically relevant mutations, and offer multiplexing capability. The advantages of the CRISPR-based diagnostic approaches are a short sample-to-answer time and no requirement of laboratory settings; they are also much more affordable than current nucleic acid detection procedures. In this review, we summarize the applications and development trends of the CRISPR/Cas13 system in the identification of particular pathogens and mutations and discuss the challenges and future prospects of CRISPR-based diagnostic platforms in biomedicine.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Robustness of Catalytically Dead Cas9 Activators in Human Pluripotent and Mesenchymal Stem Cells

  • Petazzi, Paolo|||0000-0002-1036-2895
  • Torres, Raul|||0000-0001-9606-0398
  • Fidanza, Andrea|||0000-0001-7766-0806
  • Roca Ho, Heleia|||0000-0001-7324-5234
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Castaño Cardoso, Julio|||0000-0002-0712-5856
  • Rodriguez-Perales, Sandra|||0000-0001-7221-3636
  • Díaz de la Guardia, Rafael|||0000-0001-9568-6719
  • López-Millán, Belén|||0000-0002-9757-5454
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Forrester, L. M.
  • Bueno, Clara|||0000-0003-1442-6216
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Human pluripotent stem cells (hPSCs) and mesenchymal stromal/stem cells (hMSCs) are clinically relevant sources for cellular therapies and for modeling human development and disease. Many stem cell-based applications rely on the ability to activate several endogenous genes simultaneously to modify cell fate. However, genetic intervention of these cells remains challenging. Several catalytically dead Cas9 (dCas9) proteins fused to distinct activation domains can modulate gene expression when directed to their regulatory regions by a specific single-guide RNA (sgRNA). In this study, we have compared the ability of the first-generation dCas9-VP64 activator and the second-generation systems, dCas9-SAM and dCas9-SunTag, to induce gene expression in hPSCs and hMSCs. Several stem cell lines were tested for single and multiplexed gene activation. When the activation of several genes was compared, all three systems induced specific and potent gene expression in both single and multiplexed settings, but the dCas9-SAM and dCas9-SunTag systems resulted in the highest and most consistent level of gene expression. Simultaneous targeting of the same gene with multiple sgRNAs did not result in additive levels of gene expression in hPSCs nor hMSCs. We demonstrate the robustness and specificity of second-generation dCas9 activators as tools to simultaneously activate several endogenous genes in clinically relevant human stem cells.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

RIAM-VASP Module Relays Integrin Complement Receptors in Outside-In Signaling Driving Particle Engulfment

  • Torres-Gomez, A.|||0000-0002-7377-1581
  • Sánchez-Trincado, José Luis|||0000-0002-9150-1315
  • Toribio, V.
  • Torres, Raul|||0000-0001-9606-0398
  • Torres, Raul|||0000-0001-9606-0398
  • Yáñez-Mó, María|||0000-0001-7484-2866
  • Reche, P. A.
  • Cabañas, Carlos|||0000-0002-8767-060X
  • Lafuente, E. M.|||0000-0001-8466-1022
The phagocytic integrins and complement receptors αMβ2/CR3 and αXβ2/CR4 are classically associated with the phagocytosis of iC3b-opsonized particles. The activation of this receptor is dependent on signals derived from other receptors (inside-out signaling) with the crucial involvement of the Rap1-RIAM-Talin-1 pathway. Here, we analyze the implication of RIAM and its binding partner VASP in the signaling events occurring downstream of β2 integrins (outside-in) during complement-mediated phagocytosis. To this end, we used HL-60 promyelocytic cell lines deficient in RIAM or VASP or overexpressing EGFP-tagged VASP to determine VASP dynamics at phagocytic cups. Our results indicate that RIAM-deficient HL-60 cells presented impaired particle internalization and altered integrin downstream signaling during complement-dependent phagocytosis. Similarly, VASP deficiency completely blocked phagocytosis, while VASP overexpression increased the random movement of phagocytic particles at the cell surface, with reduced internalization. Moreover, the recruitment of VASP to particle contact sites, amount of pSer157-VASP and formation of actin-rich phagocytic cups were dependent on RIAM expression. Our results suggested that RIAM worked as a relay for integrin complement receptors in outside-in signaling, coordinating integrin activation and cytoskeletal rearrangements via its interaction with VASP.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeting OGG1 arrests cancer cell proliferation by inducing replication stress

  • Visnes, Torkild|||0000-0003-1047-988X
  • Benítez-Buelga, Carlos
  • Cázares-Körner, A.
  • Sanjiv, K.
  • Hanna, Bishoy
  • Mortusewicz, O.
  • Rajagopal, Veera M.|||0000-0002-5236-168X
  • Albers, J. J.
  • Hagey, D. W.
  • Bekkhus, T.
  • Eshtad, S.
  • Baquero, Juan Miguel|||0000-0002-6488-7742
  • Masuyer, G.
  • Wallner, Olov|||0000-0002-6481-237X
  • Müller, S.
  • Pham, T.
  • Göktürk, C.
  • Rasti, A.
  • Suman, S.
  • Torres, Raul|||0000-0001-9606-0398
  • Sarno, A.
  • Wiita, E.
  • Homan, E. J.
  • Karsten, S.
  • Marimuthu, K.
  • Michel, M.
  • Koolmeister, T.
  • Scobie, M.
  • Loseva, O.
  • Almlöf, I.
  • Unterlass, J. E.
  • Pettke, A.
  • Boström, J.
  • Pandey, M.
  • Gad, H.
  • Herr, P.
  • Jemth, A. S.
  • El Andaloussi, S.
  • Kalderén, C.
  • Rodriguez-Perales, Sandra|||0000-0001-7221-3636
  • Benítez, J.
  • Krokan, H. E.
  • Altun, M.
  • Stenmark, P.
  • Berglund, U. W.
  • Helleday, Thomas|||0000-0002-7384-092X
Altered oncogene expression in cancer cells causes loss of redox homeostasis resulting in oxidative DNA damage, e.g. 8-oxoguanine (8-oxoG), repaired by base excision repair (BER). PARP1 coordinates BER and relies on the upstream 8-oxoguanine-DNA glycosylase (OGG1) to recognise and excise 8-oxoG. Here we hypothesize that OGG1 may represent an attractive target to exploit reactive oxygen species (ROS) elevation in cancer. Although OGG1 depletion is well tolerated in non-transformed cells, we report here that OGG1 depletion obstructs A3 T-cell lymphoblastic acute leukemia growth in vitro and in vivo, validating OGG1 as a potential anti-cancer target. In line with this hypothesis, we show that OGG1 inhibitors (OGG1i) target a wide range of cancer cells, with a favourable therapeutic index compared to non-transformed cells. Mechanistically, OGG1i and shRNA depletion cause S-phase DNA damage, replication stress and proliferation arrest or cell death, representing a novel mechanistic approach to target cancer. This study adds OGG1 to the list of BER factors, e.g. PARP1, as potential targets for cancer treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Small molecule inhibitor of OGG1 blocks oxidative DNA damage repair at telomeres and potentiates methotrexate anticancer effects

  • Baquero, Juan Miguel|||0000-0002-6488-7742
  • Benítez-Buelga, Carlos
  • Rajagopal, Varshni
  • Zhenjun, Zhao
  • Torres, Raul|||0000-0001-9606-0398
  • Müller, Sarah
  • Hanna, Bishoy M. F.|||0000-0001-7027-6553
  • Loseva, Olga
  • Wallner, Olov|||0000-0002-6481-237X
  • Michel, Maurice|||0000-0003-3261-2493
  • Rodriguez-Perales, Sandra|||0000-0001-7221-3636
  • Gad, Helge|||0000-0001-6530-1443
  • Visnes, Torkild|||0000-0003-1047-988X
  • Helleday, Thomas|||0000-0002-7384-092X
  • Benitez, Javier|||0000-0002-0923-7202
  • Osorio, Ana|||0000-0001-8124-3984
The most common oxidative DNA lesion is 8-oxoguanine which is mainly recognized and excised by the 8-oxoG DNA glycosylase 1 (OGG1), initiating the base excision repair (BER) pathway. Telomeres are particularly sensitive to oxidative stress (OS) which disrupts telomere homeostasis triggering genome instability. In the present study, we have investigated the effects of inactivating BER in OS conditions, by using a specific inhibitor of OGG1 (TH5487). We have found that in OS conditions, TH5487 blocks BER initiation at telomeres causing an accumulation of oxidized bases, that is correlated with telomere losses, micronuclei formation and mild proliferation defects. Moreover, the antimetabolite methotrexate synergizes with TH5487 through induction of intracellular reactive oxygen species (ROS) formation, which potentiates TH5487-mediated telomere and genome instability. Our findings demonstrate that OGG1 is required to protect telomeres from OS and present OGG1 inhibitors as a tool to induce oxidative DNA damage at telomeres, with the potential for developing new combination therapies for cancer treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The insecticides permethrin and chlorpyrifos show limited genotoxicity and no leukemogenic potential in human and murine hematopoietic stem progenitor cells

  • Rodriguez-Cortez, Virginia C.
  • Navarrete-Meneses, Maria Pilar
  • Molina, Oscar|||0000-0001-7585-4519
  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • González, Jéssica
  • Romecín, Paola Alejandra|||0000-0001-6890-5883
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Roca Ho, Heleia|||0000-0001-7324-5234
  • Vinyoles, Meritxell|||0000-0003-1906-4701
  • Kowarz, Eric
  • Marin, Pedro
  • Rodriguez-Perales, Sandra|||0000-0001-7221-3636
  • Gomez-Marin, Carlos
  • Perez-Vera, Patricia
  • Cortes-Ledesma, Felipe
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Terron, Andrea
  • Bueno, Clara|||0000-0003-1442-6216
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A faecal microbiota signature with high specificity for pancreatic cancer

  • Kartal, Ece|||0000-0002-7720-455X
  • Schmidt, Thomas S B.|||0000-0001-8587-4177
  • Molina Montes, Esther|||0000-0002-0428-2426
  • Rodriguez-Perales, Sandra|||0000-0001-7221-3636
  • Wirbel, Jakob|||0000-0002-4073-3562
  • Maistrenko, Oleksandr M.|||0000-0003-1961-7548
  • Akanni, Wasiu A.|||0000-0002-2075-2387
  • Alashkar Alhamwe, Bilal|||0000-0002-7120-0013
  • Alves, Renato J.|||0000-0002-7212-0234
  • Carrato, Alfredo|||0000-0001-7749-8140
  • Erasmus, Hans Peter
  • Estudillo, Lidia|||0000-0003-3891-3713
  • Finkelmeier, Fabian
  • Fullam, Anthony|||0000-0002-0884-8124
  • Glazek, Anna M.
  • Gómez-Rubio, Paulina
  • Hercog, Rajna
  • Jung, Ferris|||0000-0002-5534-7832
  • Kandels, Stefanie|||0000-0002-4194-4927
  • Kersting, Stephan|||0000-0002-2124-3103
  • Langheinrich, Melanie|||0000-0002-0120-9135
  • Márquez, Mirari
  • Molero, Xavier|||0000-0003-2473-7405
  • Orakov, Askarbek|||0000-0001-6823-5269
  • Van Rossum, Thea|||0000-0002-3598-5001
  • Torres, Raul|||0000-0001-9606-0398
  • Telzerow, Anja|||0000-0001-9855-0809
  • Zych, Konrad|||0000-0001-7426-0516
  • Benes, Vladimir|||0000-0002-0352-2547
  • Zeller, Georg|||0000-0003-1429-7485
  • Trebicka, Jonel|||0000-0002-7028-3881
  • Real, Francisco X.|||0000-0001-9501-498X
  • Malats, Núria|||0000-0003-2538-3784
  • Bork, Peer|||0000-0002-2627-833X
  • Ilzarbe, Lucas|||0000-0003-1798-6876
  • Alvarez-Urturi, Cristina|||0000-0002-7305-9973
  • Bessa Caserras, Xavier|||0000-0003-4680-1228
  • Bory, Felipe
  • Márquez Mosquera, Lucía|||0000-0002-3182-9570
  • Poves, Ignasi
  • Burdío, Fernando|||0000-0003-3038-0086
  • Grande, L.|||0000-0001-9146-9004
  • Gimeno Beltran, Javier|||0000-0001-6085-5228
  • Guarner, Luisa
  • Balcells, Joaquin
  • Salcedo, Mayte
  • Farré, Antoni|||0000-0003-1279-8868
  • Mora Brugués, Josefina|||0000-0001-6777-5132
  • Martín Flix, Marta|||0000-0001-7849-3616
  • Artigas Raventos, Vicens|||0000-0002-2874-2490
  • Guarner, Carlos|||0000-0001-5957-9481
  • Sancho, Francesc J.
  • Concepción, Mar|||0000-0003-1821-0359
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
Recent evidence suggests a role for the microbiome in pancreatic ductal adenocarcinoma (PDAC) aetiology and progression. To explore the faecal and salivary microbiota as potential diagnostic biomarkers. We applied shotgun metagenomic and 16S rRNA amplicon sequencing to samples from a Spanish case-control study (n=136), including 57 cases, 50 controls, and 29 patients with chronic pancreatitis in the discovery phase, and from a German case-control study (n=76), in the validation phase. Faecal metagenomic classifiers performed much better than saliva-based classifiers and identified patients with PDAC with an accuracy of up to 0.84 area under the receiver operating characteristic curve (AUROC) based on a set of 27 microbial species, with consistent accuracy across early and late disease stages. Performance further improved to up to 0.94 AUROC when we combined our microbiome-based predictions with serum levels of carbohydrate antigen (CA) 19-9, the only current non-invasive, Food and Drug Administration approved, low specificity PDAC diagnostic biomarker. Furthermore, a microbiota-based classification model confined to PDAC-enriched species was highly disease-specific when validated against 25 publicly available metagenomic study populations for various health conditions (n=5792). Both microbiome-based models had a high prediction accuracy on a German validation population (n=76). Several faecal PDAC marker species were detectable in pancreatic tumour and non-tumour tissue using 16S rRNA sequencing and fluorescence in situ hybridisation. Taken together, our results indicate that non-invasive, robust and specific faecal microbiota-based screening for the early detection of PDAC is feasible.